Cytokine Inhibition as a Potential Therapy for ANCA-Associated Glomerulonephritis

细胞因子抑制作为 ANCA 相关肾小球肾炎的潜在疗法

• 批准号: nhmrc : GNT1128267
• 负责人: Prof Arthur Kitching
• 金额: $ 92.96万
• 依托单位: Monash University
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2017
• 资助国家: 澳大利亚
• 起止时间: 2017-01-01 至 无数据
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/cytokine-inhibition-potential-associated-glomerulonephritis/1347677
• 关键词: Cytokine; Inhibition; Potential; Therapy; ANCA

MPO-ANCA associated glomerulonephritis is a major cause of renal failure. Current treatments are toxic and poorly effective. Cytokines are immune proteins that direct disease. New biological anti-cytokine treatments are effective but not available for kidney diseases. This study will define the key cytokines driving this disease and provide proof of safety and efficacy in our animal model of this disease. This evidence will allow the introduction of anti-cytokine biologicals in clinical trials.

MPO-ANCA相关性肾小球肾炎是肾衰竭的主要原因。目前的治疗方法有毒且效果不佳。细胞因子是引导疾病的免疫蛋白。新的生物抗细胞因子治疗是有效的，但不能用于肾脏疾病。这项研究将确定驱动这种疾病的关键细胞因子，并在我们的这种疾病的动物模型中提供安全性和有效性的证据。这一证据将允许在临床试验中引入抗细胞因子生物制剂。